Ticker

LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced that the Company has made a grant of options to purchase an aggregate of 17,000 of the Company's common shares to a new employee on July 1, 2026 ("Grant"). The Grant was offered as material inducement to the employee's…

100 r/r DLBCL patients treated at the selected 150 µg/kg dose of ZYNLONTA® plus glofitamab Full data expected in fourth quarter of 2026 LAUSANNE, Switzerland, June 30, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced the completion of enrollment in the LOTIS-7 Phase 1b open-label clinical trial…

NEW YORK, June 25, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and clinical milestones, including planned LOTIS-5 sBLA submission and full LOTIS-7 data by end of 2026 LAUSANNE, Switzerland, June 24, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and…

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA (“ADC” or the “Company”) (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext. 7980.